Drugs for Metastatic Kidney Cancer Equally Effective, Study Shows

Share this content:

A phase 3 trial has found pazopanib (Votrient) and sunitinib (Sutent) are both equally effective for treating metastatic kidney cancer.

However, the trial suggests that one agent appears to be much better tolerated.

John Schieszer has the story in today's Medical Minute.

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters